11:23 AM EDT, 05/13/2025 (MT Newswires) -- NRX Pharmaceuticals ( NRXP ) said Tuesday its subsidiary Hope Therapeutics has entered into a definitive agreement to acquire the Kadima Neuropsychiatry Institute, an interventional psychiatry clinic based in California.

Financial terms of the transaction were not disclosed.

Kadima founder and medical director Dr. David Feifel will join Hope as its first chief medical innovation officer upon the closing of the acquisition, the company said.

Feifel has served as an elected member of the American College of Neuropharmacology and has held roles in multiple clinical trials for CNS therapies, according to the statement.

Shares of NRX Pharmaceuticals ( NRXP ) were up 2.6% in recent trading.

Price: 2.14, Change: +0.05, Percent Change: +2.64